AL AMYLOIDOSIS

This study looks at whether a shorter or longer course of daratumumab maintenance therapy works better for people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 96 adults who have already responded to initial daratumumab treatment will be as…

This study tests a drug called elranatamab in people with AL amyloidosis that has come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can reduce abnormal protein levels in the blood. About 49 adults will take part in this early-phase…

This study tests a drug called teclistamab in 30 adults with AL amyloidosis that has not responded well to previous treatments. The goal is to see if the drug can reduce or eliminate the abnormal proteins causing organ damage. Participants will receive teclistamab and be monitore…

This study tests a drug called belantamab mafodotin in people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The goal is to find the safest and most effective dose to control the disease. About 37 participants will be enrolled, and the study has t…

This study is for people newly diagnosed with AL amyloidosis who have a specific genetic change called t(11;14). The goal is to improve treatment by starting with a standard drug combination and then switching to a more targeted therapy if the disease does not respond quickly. Ab…

This study tests whether adding a stem cell transplant to standard chemotherapy works better than chemotherapy alone for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins damage organs. About 338 participants will receive either chemo plus a stem …

This study tests whether a special PET scan using a radioactive tracer called [18F]Florbetaben can accurately diagnose cardiac AL amyloidosis, a rare condition where abnormal proteins build up in the heart. About 200 adults with suspected cardiac amyloidosis will receive one inje…

This study connects Italian hospitals to a specialized center to find AL amyloidosis earlier in people with related blood conditions. Researchers will screen 760 participants using blood tests and track their health over time. The goal is to speed up diagnosis and learn more abou…

This study is creating a large database of up to 5,000 people in Ohio with plasma cell disorders like multiple myeloma and amyloidosis. Researchers will track treatments, outcomes, and quality of life, while also offering patients access to expert consultations and information ab…

This study looks at a specific gene (IGLV1-44) to understand why it causes two rare diseases: AL amyloidosis and POEMS syndrome. Researchers will analyze blood and bone marrow samples from 100 adults with these conditions or multiple myeloma. The goal is to find genetic patterns …

This study is creating a large European registry of 400 newly diagnosed AL amyloidosis patients. Researchers will collect medical data and blood samples to study the disease using advanced technology. The goal is to improve diagnosis and management of this rare condition, not to …

This study looks at how sugar molecules attached to proteins might cause or worsen AL amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect blood and bone marrow samples from 100 adults with related conditions to understand this process.…

This study is creating a biobank and data registry for people with amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect blood, urine, and tissue samples along with medical information from 505 participants. The goal is to store these ma…

This study is building a large registry of 5000 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. Researchers will collect information from medical records and follow-ups to learn how the disease progresses and how current treatments affect it…